STAT+: FDA’s rejection of Humanigen drug highlights problems in developing Covid-19 treatments

The Food and Drug Administration has declined to grant emergency use authorization to lenzilumab, an experimental drug developed by Humanigen, for the treatment of hospitalized patients with Covid-19, the company said Thursday.

“In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19,” Humanigen said.

Continue to STAT+ to read the full story…

STAT+: FDA’s rejection of Humanigen drug highlights problems in developing Covid-19 treatments

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top